NZ712369A - 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists - Google Patents

5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists

Info

Publication number
NZ712369A
NZ712369A NZ712369A NZ71236913A NZ712369A NZ 712369 A NZ712369 A NZ 712369A NZ 712369 A NZ712369 A NZ 712369A NZ 71236913 A NZ71236913 A NZ 71236913A NZ 712369 A NZ712369 A NZ 712369A
Authority
NZ
New Zealand
Prior art keywords
quinoline
receptor agonists
amino
carboxamide derivatives
formula
Prior art date
Application number
NZ712369A
Other languages
English (en)
Inventor
Ramakrishna Nirogi
Anil Karbhari Shinde
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of NZ712369A publication Critical patent/NZ712369A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82Translation products from oncogenes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
NZ712369A 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists NZ712369A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1199CH2013 IN2013CH01199A (enExample) 2013-03-20 2013-10-18
PCT/IN2013/000639 WO2014147636A1 (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists

Publications (1)

Publication Number Publication Date
NZ712369A true NZ712369A (en) 2016-11-25

Family

ID=54325095

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ712369A NZ712369A (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists

Country Status (18)

Country Link
US (1) US9790211B2 (enExample)
EP (1) EP2976337B1 (enExample)
JP (1) JP6185650B2 (enExample)
KR (1) KR101815307B1 (enExample)
CN (1) CN105164119B (enExample)
AP (1) AP2015008742A0 (enExample)
AU (1) AU2013382944B2 (enExample)
BR (1) BR112015024060A2 (enExample)
CA (1) CA2907620C (enExample)
DK (1) DK2976337T3 (enExample)
EA (1) EA029365B1 (enExample)
ES (1) ES2674993T3 (enExample)
IN (1) IN2013CH01199A (enExample)
MX (1) MX364929B (enExample)
NZ (1) NZ712369A (enExample)
SG (1) SG11201507763RA (enExample)
WO (1) WO2014147636A1 (enExample)
ZA (1) ZA201506804B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ734400A (en) * 2015-02-13 2018-03-23 Suven Life Sciences Ltd Amide compounds as 5-ht4 receptor agonists
CN109444301A (zh) * 2018-12-18 2019-03-08 江苏省中医院 一种测定血浆中普芦卡必利浓度的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008994A1 (en) * 1992-10-13 1994-04-28 Smithkline Beecham Plc Heterocyclic -esters or -amides used as 5-ht4 receptor antagonists
WO1994010174A1 (en) 1992-11-05 1994-05-11 Smithkline Beecham Plc Piperidine derivatives as 5-ht4 receptor antagonists
FR2756564B1 (fr) * 1996-12-04 2004-05-14 Synthelabo Derives d'acide quinoleine-8-carboxylique, leur preparation et leur application en therapeutique
WO2001095903A1 (en) * 2000-06-15 2001-12-20 Respiratorius Ab 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
AU2004254193B2 (en) * 2003-06-19 2010-02-18 Janssen Pharmaceutica N.V. 5ht4-antagonistic 4-(aminomethyl)-piperidine benzamides
CA2545092C (en) 2003-11-24 2010-08-17 Pfizer Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
DK1701951T3 (da) * 2003-12-23 2010-06-07 Serodus As Modulatorer af perifere 5-HT receptorer
WO2005092882A1 (en) * 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
US8816090B2 (en) 2005-02-25 2014-08-26 Pfizer Inc. Benzisoxazole derivatives
ATE449092T1 (de) 2005-07-22 2009-12-15 Pfizer Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors
GB0525661D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Novel compounds
RU2569733C2 (ru) * 2010-02-12 2015-11-27 Раквалиа Фарма Инк. Агонисты 5-нт4-рецепторов для лечения деменции
JP2013519722A (ja) 2010-02-16 2013-05-30 ファイザー・インク (r)−4−((4−((4−(テトラヒドロフラン−3−イルオキシ)ベンゾ[d]イソオキサゾール−3−イルオキシ)メチル)ピペリジン−1−イル)メチル)テトラヒドロ−2h−ピラン−4−オール、5−ht4受容体の部分アゴニスト

Also Published As

Publication number Publication date
AU2013382944A1 (en) 2015-10-08
BR112015024060A2 (pt) 2017-07-18
CA2907620A1 (en) 2014-09-25
WO2014147636A8 (en) 2014-12-04
JP2016516089A (ja) 2016-06-02
KR20160004274A (ko) 2016-01-12
EP2976337B1 (en) 2018-05-02
IN2013CH01199A (enExample) 2015-08-14
HK1217483A1 (zh) 2017-01-13
EA029365B1 (ru) 2018-03-30
KR101815307B1 (ko) 2018-01-04
US9790211B2 (en) 2017-10-17
WO2014147636A1 (en) 2014-09-25
DK2976337T3 (en) 2018-07-16
AP2015008742A0 (en) 2015-09-30
MX2015012350A (es) 2016-05-09
US20160280694A1 (en) 2016-09-29
ES2674993T3 (es) 2018-07-05
ZA201506804B (en) 2016-07-27
CA2907620C (en) 2018-03-13
JP6185650B2 (ja) 2017-08-23
EA201591844A1 (ru) 2016-08-31
EP2976337A1 (en) 2016-01-27
SG11201507763RA (en) 2015-10-29
AU2013382944B2 (en) 2016-08-04
CN105164119B (zh) 2017-12-08
MX364929B (es) 2019-05-14
CN105164119A (zh) 2015-12-16

Similar Documents

Publication Publication Date Title
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
MD20150071A2 (ro) Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
MX2016005759A (es) Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12016500985A1 (en) Use of benzimidazole-proline derivatives
PH12017500089B1 (en) Aldosterone synthase inhibitors
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
MY176521A (en) Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
NZ720879A (en) Indazole compounds as 5-ht4 receptor agonists
PH12015502746A1 (en) Prodrug derivatives of substituted triazolopyridines
MX2015000064A (es) Compuestos de acrilamida como ligandos receptores de histamina h3.
NZ712369A (en) 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
PH12015502703A1 (en) Pharmaceutical compositions
IN2013MU03838A (enExample)
MX2015012393A (es) Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 OCT 2018 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20170719

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 OCT 2019 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20180726

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 OCT 2020 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20190724

LAPS Patent lapsed